
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Trending on Applied Clinical Trials Online
1
AI-Enabled Sites and the Future of Trial Planning: Q&A with Liz Beatty, Inato
2
ACT Brief: CTTI Risk Myth-Busting, Hidden ePRO Exclusion Criteria, and Patient-Centered Care Models
3
Operational Pragmatism in ePRO-heavy trials
4
ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots
5